Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Full year 2025 revenue totals
Xtant delivers positive net income, adjusted EBITDA and operating cash flow
Total cash of
Fourth Quarter 2025 Financial Highlights
- Revenue of
$32.4 million , up approximately 3% compared to the prior year quarter- Company's earlier-than-anticipated closing of the Companion Spine transaction reduced fourth quarter 2025 revenue by an estimated
$2.0 million
- Company's earlier-than-anticipated closing of the Companion Spine transaction reduced fourth quarter 2025 revenue by an estimated
- Gross margin of 54.9% compared to 50.8% for the prior year quarter
- Net income of
$0.1 million compared to a net loss of$3.2 million in the prior year quarter - Non-GAAP adjusted EBITDA of
$1.9 million compared to adjusted EBITDA of$0.4 million in the prior year quarter
Full-Year 2025 Financial Highlights
- Revenue of
$134.0 million , up approximately 14% over the full-year 2024 - Gross margin of 62.9%, compared to 58.2% for the full year 2024
- Net income of
$5.0 million , or$0.03 per diluted share, compared to a net loss of$16.5 million , or a net loss of$0.12 per basic and diluted share, for the full year 2024 - Non-GAAP adjusted EBITDA of
$16.3 million compared to an adjusted EBITDA loss of$2.3 million for the full year 2024 - Net cash provided by operations of
$12.5 million compared to net cash used in operations of$11.9 million for the full year 2024
Fourth Quarter 2025 and Recent Business Highlights
- Completed the previously announced sale of Xtant's non-core Coflex® and
CoFix assets and its international hardware businesses to Companion Spine for a total sale price of$21.4 million in cash. - Announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™. nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with higher solubility than traditional hydroxyapatite (HA), the most commonly used synthetic material.
- Announced the commercial launch of CollagenX™, its bovine collagen particulate product for surgical wound closure designed to promote healing, prevent dehiscence, and help mitigate concerns related to surgical site infections.
"Looking ahead to 2026, with the recent receipt of amounts previously outstanding under our note receivable from the Companion Spine transaction, we have increased our current cash position to over
Fourth Quarter and Full-Year 2025 Financial Results
Fourth quarter 2025 revenue grew 3% to
Gross margin for the fourth quarter of 2025 was 54.9%, compared to 50.8% for the same period in 2024. For the full year 2025, gross margin was 62.9%, compared to 58.2% for the full year 2024. These increases were primarily attributable to sales mix and greater scale, partially offset by increased charges for excess and obsolete inventory, in particular, a
Operating expenses for the fourth quarter of 2025 totaled
Net income for the fourth quarter 2025 totaled
Non-GAAP adjusted EBITDA for the fourth quarter of 2025 totaled
The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, separation-related expenses, non-cash compensation, disposition/acquisition-related expense, acquisition-related fair value adjustments, gain on divestiture, and unrealized foreign currency translation gain or loss. A calculation and reconciliation of adjusted EBITDA to net income (loss) can be found in the attached financial tables.
As of
2026 Financial Guidance
The Company anticipates full-year 2026 revenue to be in the range of
Conference Call
To access the webcast: https://www.webcaster5.com/Webcast/Page/3039/53616
To access the conference call, dial 888-506-0062 (US) or 973-528-0011 (International) and reference Participant Access Code 581090.
A replay of the call will be available on the Investor section of the Company's website at www.xtantmedical.com for a period of one year.
About
The symbols ™ and ® denote trademarks and registered trademarks of
Non-GAAP Financial Measures
To supplement the Company's consolidated financial statements prepared in accordance with
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," "going forward," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's full year 2026 revenue guidance, anticipated organic growth in its core higher-margin biologics business, need for no further capital to fund its operations and expectation to be free cash flow positive in 2026. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results, financial performance and need for additional capital; the success of the Company's expanded field sales force to improve the Company's reach and leverage its outstanding contract portfolio and independent agent network; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with acquisitions and dispositions; its ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; the effect of government and third-party coverage and reimbursement for its products; its ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; its ability to license intellectual property on commercially reasonable terms and to maintain any such licenses and its ability to obtain and protect its intellectual property and proprietary rights and operate without infringing the rights of others; its ability to service its debt, comply with debt covenants, and access additional indebtedness or financing on favorable terms or at all, if and when needed; and other factors described in its Annual Report on Form 10-K for the year ended
-- Tables Follow –
|
|
||||||||
|
|
||||||||
|
|
|
As of
|
|
|
As of
|
|
||
|
ASSETS |
|
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
|
Cash and cash-equivalents |
|
$ |
17,053 |
|
|
$ |
6,199 |
|
|
Restricted cash |
|
|
275 |
|
|
|
22 |
|
|
Trade accounts receivable, net of allowance for credit losses of |
|
|
17,803 |
|
|
|
20,660 |
|
|
Inventories |
|
|
30,263 |
|
|
|
38,634 |
|
|
Note receivable |
|
|
10,462 |
|
|
|
— |
|
|
Prepaid and other current assets |
|
|
2,389 |
|
|
|
1,601 |
|
|
Total current assets |
|
|
78,245 |
|
|
|
67,116 |
|
|
Property and equipment, net |
|
|
6,202 |
|
|
|
10,131 |
|
|
Right of use asset, net |
|
|
3,192 |
|
|
|
829 |
|
|
|
|
|
6,074 |
|
|
|
7,302 |
|
|
Intangible assets, net |
|
|
299 |
|
|
|
8,356 |
|
|
Other assets |
|
|
133 |
|
|
|
103 |
|
|
Total Assets |
|
$ |
94,145 |
|
|
$ |
93,837 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES & STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
3,844 |
|
|
$ |
7,918 |
|
|
Accrued liabilities |
|
|
10,626 |
|
|
|
7,771 |
|
|
Current portion of long-term debt |
|
|
3,500 |
|
|
|
— |
|
|
Current portion of lease liability |
|
|
622 |
|
|
|
703 |
|
|
Current portion of finance lease obligations |
|
|
35 |
|
|
|
69 |
|
|
Line of credit |
|
|
10,857 |
|
|
|
12,120 |
|
|
Total current liabilities |
|
|
29,484 |
|
|
|
28,581 |
|
|
Long-term Liabilities: |
|
|
|
|
|
|
|
|
|
Lease liability, net |
|
|
2,665 |
|
|
|
166 |
|
|
Financing lease obligations, net |
|
|
12 |
|
|
|
47 |
|
|
Long-term debt, plus premium and less issuance costs |
|
|
11,026 |
|
|
|
22,038 |
|
|
Deferred tax liability |
|
|
5 |
|
|
|
42 |
|
|
Total Liabilities |
|
|
43,192 |
|
|
|
50,874 |
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies (Note 12) |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' Equity: |
|
|
|
|
|
|
|
|
|
Preferred stock, |
|
|
— |
|
|
|
— |
|
|
Common stock, |
|
|
— |
|
|
|
— |
|
|
Additional paid-in capital |
|
|
305,439 |
|
|
|
302,738 |
|
|
Accumulated other comprehensive income |
|
|
— |
|
|
|
(316) |
|
|
Accumulated deficit |
|
|
(254,486) |
|
|
|
(259,459) |
|
|
Total Stockholders' Equity |
|
|
50,953 |
|
|
|
42,963 |
|
|
Total Liabilities & Stockholders' Equity |
|
$ |
94,145 |
|
|
$ |
93,837 |
|
|
|
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
Three Months Ended |
|
|
Twelve Months Ended |
|
||||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue |
|
$ |
27,712 |
|
|
$ |
30,011 |
|
|
$ |
115,204 |
|
|
$ |
115,765 |
|
|
License revenue |
|
|
4,645 |
|
|
|
1,502 |
|
|
|
18,723 |
|
|
|
1,502 |
|
|
Total Revenue |
|
|
32,357 |
|
|
|
31,513 |
|
|
|
133,927 |
|
|
|
117,267 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of Sales |
|
|
14,603 |
|
|
|
15,489 |
|
|
|
49,654 |
|
|
|
49,051 |
|
|
Gross Profit |
|
|
17,754 |
|
|
|
16,024 |
|
|
|
84,273 |
|
|
|
68,216 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative |
|
|
7,293 |
|
|
|
5,700 |
|
|
|
29,375 |
|
|
|
28,691 |
|
|
Sales and marketing |
|
|
10,946 |
|
|
|
11,684 |
|
|
|
45,512 |
|
|
|
49,214 |
|
|
Research and development |
|
|
459 |
|
|
|
522 |
|
|
|
2,102 |
|
|
|
2,385 |
|
|
Total Operating Expenses |
|
|
18,698 |
|
|
|
17,906 |
|
|
|
76,989 |
|
|
|
80,290 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (Loss) from Operations |
|
|
(944) |
|
|
|
(1,882) |
|
|
|
7,284 |
|
|
|
(12,074) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expense) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(718) |
|
|
|
(1,134) |
|
|
|
(3,671) |
|
|
|
(4,160) |
|
|
Interest income |
|
|
94 |
|
|
|
— |
|
|
|
94 |
|
|
|
— |
|
|
Unrealized foreign currency translation (loss) |
|
|
(206) |
|
|
|
(101) |
|
|
|
(60) |
|
|
|
5 |
|
|
Gain on divestiture |
|
|
3,281 |
|
|
|
— |
|
|
|
3,281 |
|
|
|
— |
|
|
Other income (expense) |
|
|
91 |
|
|
|
(27) |
|
|
|
73 |
|
|
|
(33) |
|
|
Total Other Income (Expense) |
|
|
2,542 |
|
|
|
(1,262) |
|
|
|
(283) |
|
|
|
(4,188) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income (Loss) from Operations Before |
|
|
1,598 |
|
|
|
(3,144) |
|
|
|
7,001 |
|
|
|
(16,262) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for Income Taxes Current and |
|
|
(1,541) |
|
|
|
(21) |
|
|
|
(2,028) |
|
|
|
(187) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income (Loss) |
|
$ |
57 |
|
|
$ |
(3,165) |
|
|
$ |
4,973 |
|
|
$ |
(16,449) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income (Loss) Per Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.00 |
|
|
$ |
(0.02) |
|
|
$ |
0.04 |
|
|
$ |
(0.12) |
|
|
Dilutive |
|
$ |
0.00 |
|
|
$ |
(0.02) |
|
|
$ |
0.03 |
|
|
$ |
(0.12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in the computation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
139,826,783 |
|
|
|
138,977,615 |
|
|
|
139,531,791 |
|
|
|
133,665,075 |
|
|
Dilutive |
|
|
150,462,888 |
|
|
|
138,977,615 |
|
|
|
150,042,556 |
|
|
|
133,665,075 |
|
|
|
|
|||||||
|
|
|
|||||||
|
|
|
Year Ended |
|
|||||
|
|
|
2025 |
|
|
2024 |
|
||
|
Operating activities: |
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
4,973 |
|
|
$ |
(16,449) |
|
|
Adjustments to reconcile net income (loss) to net cash provided by (used in) |
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
5,223 |
|
|
|
4,224 |
|
|
Non-cash interest |
|
|
537 |
|
|
|
522 |
|
|
Loss (gain) on sale of fixed assets |
|
|
251 |
|
|
|
(264) |
|
|
Stock-based compensation |
|
|
2,892 |
|
|
|
4,117 |
|
|
Provision for reserve on accounts receivable |
|
|
1,404 |
|
|
|
823 |
|
|
Provision for excess and obsolete inventory |
|
|
3,669 |
|
|
|
485 |
|
|
Gain on sale to Companion |
|
|
(3,281) |
|
|
|
— |
|
|
Other |
|
|
(76) |
|
|
|
(5) |
|
|
|
|
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities, net of the effects of acquisitions: |
|
|
|
|
|
|
|
|
|
Trade accounts receivable |
|
|
(591) |
|
|
|
(755) |
|
|
Inventories |
|
|
(1,999) |
|
|
|
(2,494) |
|
|
Prepaid and other assets |
|
|
(1,537) |
|
|
|
(218) |
|
|
Accounts payable |
|
|
(3,117) |
|
|
|
1,033 |
|
|
Accrued liabilities |
|
|
4,198 |
|
|
|
(2,915) |
|
|
Net cash provided by (used in) operating activities |
|
|
12,546 |
|
|
|
(11,896) |
|
|
|
|
|
|
|
|
|
|
|
|
Investing activities: |
|
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(2,382) |
|
|
|
(4,113) |
|
|
Proceeds from sale of fixed assets |
|
|
232 |
|
|
|
383 |
|
|
Proceeds from sale to Companion, net of promissory note |
|
|
10,049 |
|
|
|
— |
|
|
Net cash provided by (used in) investing activities |
|
|
7,899 |
|
|
|
(3,730) |
|
|
|
|
|
|
|
|
|
|
|
|
Financing activities: |
|
|
|
|
|
|
|
|
|
Borrowings on line of credit |
|
|
100,066 |
|
|
|
112,640 |
|
|
Repayments on line of credit |
|
|
(101,329) |
|
|
|
(105,142) |
|
|
Payments on long-term debt |
|
|
(8,000) |
|
|
|
— |
|
|
Payments on financing leases |
|
|
(67) |
|
|
|
(65) |
|
|
Proceeds from private placement, net of issuance costs |
|
|
(65) |
|
|
|
4,456 |
|
|
Proceeds from issuance of long-term debt |
|
|
— |
|
|
|
5,000 |
|
|
Debt issuance costs |
|
|
(49) |
|
|
|
(651) |
|
|
Payment of taxes from withholding of common stock upon vesting and |
|
|
(126) |
|
|
|
(178) |
|
|
Proceeds from exercise of stock-based compensation |
|
|
— |
|
|
|
13 |
|
|
Net cash (used in) provided by financing activities |
|
|
(9,570) |
|
|
|
16,073 |
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents and restricted cash |
|
|
232 |
|
|
|
(149) |
|
|
|
|
|
|
|
|
|
|
|
|
Net change in cash and cash equivalents and restricted cash |
|
|
11,107 |
|
|
|
298 |
|
|
Cash and cash equivalents and restricted cash at beginning of year |
|
|
6,221 |
|
|
|
5,923 |
|
|
Cash and cash equivalents and restricted cash at end of year |
|
$ |
17,328 |
|
|
$ |
6,221 |
|
|
Reconciliation of cash and cash equivalents and restricted cash reported in the |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
17,053 |
|
|
$ |
6,199 |
|
|
Restricted cash |
|
|
275 |
|
|
|
22 |
|
|
Total cash and cash equivalents and restricted cash reported in the consolidated |
|
$ |
17,328 |
|
|
$ |
6,221 |
|
|
|
||||||||||||||||
|
|
|
|
|
|||||||||||||
|
|
|
Three Months Ended |
|
|
Year Ended |
|
||||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net Income (Loss) |
|
$ |
57 |
|
|
$ |
(3,165) |
|
|
$ |
4,973 |
|
|
$ |
(16,449) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
1,819 |
|
|
|
1,148 |
|
|
|
5,223 |
|
|
|
4,224 |
|
|
Interest expense, net |
|
|
624 |
|
|
|
1,134 |
|
|
|
3,577 |
|
|
|
4,160 |
|
|
Tax expense |
|
|
1,541 |
|
|
|
21 |
|
|
|
2,028 |
|
|
|
187 |
|
|
Non-GAAP EBITDA |
|
|
4,041 |
|
|
|
(862) |
|
|
|
15,801 |
|
|
|
(7,878) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income (Loss)/Total Revenue |
|
|
0.2 |
% |
|
|
-10.0 |
% |
|
|
3.7 |
% |
|
|
-14.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP EBITDA/Total Revenue |
|
|
12.5 |
% |
|
|
-2.7 |
% |
|
|
11.8 |
% |
|
|
-6.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NON-GAAP ADJUSTED EBITDA CALCULATION |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash compensation |
|
|
727 |
|
|
|
840 |
|
|
|
2,892 |
|
|
|
4,117 |
|
|
Gain on divestiture |
|
|
(3,281) |
|
|
|
— |
|
|
|
(3,281) |
|
|
|
— |
|
|
Divestiture/acquisition-related expenses |
|
|
122 |
|
|
|
— |
|
|
|
491 |
|
|
|
338 |
|
|
Acquisition-related fair value adjustments |
|
|
47 |
|
|
|
167 |
|
|
|
358 |
|
|
|
415 |
|
|
Unrealized foreign currency translation loss (gain) |
|
|
206 |
|
|
|
101 |
|
|
|
60 |
|
|
|
(5) |
|
|
Separation related expenses |
|
|
— |
|
|
|
192 |
|
|
|
23 |
|
|
|
682 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Adjusted EBITDA |
|
$ |
1,862 |
|
|
$ |
438 |
|
|
$ |
16,344 |
|
|
$ |
(2,331) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Adjusted EBITDA/Total Revenue |
|
|
5.8 |
% |
|
|
1.4 |
% |
|
|
12.2 |
% |
|
|
-2.0 |
% |
View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-reports-fourth-quarter-and-full-year-2025-financial-results-302729503.html
SOURCE
